Background
==========

Clear cell renal cell carcinoma (CCRCC) is characterized by inactivation of the von Hipple-Lindau (VHL) pathway caused by somatic mutations or methylation of the VHL gene in the majority of patients. The VHL gene product is involved in the regulation of a transcription factor called hypoxia-inducible factor (HIF), which is a heterodimer of an α and β subunit. In cells with deficient or aberrant VHL protein, HIFα accumulates and binds to HIFβ. The resultant increased production of vascular endothelial growth factor (VEGF) is considered to be fundamental to the highly angiogenic nature of CCRCC and critical to oncogenesis \[[@B1],[@B2]\]. Anti-angiogenesis treatment for CCRCC includes the use of several inhibitors of VEGF and its cognate receptor VEGF receptor (VEGFR) 2 that have dramatic antitumor activity in CCRCC \[[@B3]\]. Several studies have reported that some molecular markers (tissue Ki-67, tissue p53, tissue VEGFR-1, tissue VEGF-D and serum carbonic anhydrase IX) could predict disease-free survival after nephrectomy for nonmetastatic CCRCC \[[@B4],[@B5]\].

Studies have shown that serum levels of VEGF and tumor VEGF expression are useful predictors of prognosis in RCC \[[@B6]-[@B8]\]. However, to our knowledge, there have been very few reports regarding the association between VEGF and recurrence after nephrectomy in nonmetastatic CCRCC \[[@B5],[@B9]\]. Previously, we reported that the pretreatment serum level of VEGF correlated with postoperative recurrence in patients with nonmetastatic CCRCC \[[@B9]\]. In the present study, we evaluated whether preoperative serum VEGF levels and expression of VEGF, assessed using immunohistochemistry (IHC), could predict postoperative recurrence in patients with nonmetastatic CCRCC. The discovery of reliable biomarkers in CCRCC could have an important impact on diagnosis, prognosis and prediction of therapeutic benefit.

Methods
=======

Patients
--------

A total of 83 patients with nonmetastatic CCRCC, who underwent radical nephrectomy at the Kyorin University Hospital between August 2001 and March 2010, were enrolled in the study. Initial clinical stage determination consisted of a physical examination, computed tomography (CT) and a bone scan. Data on variables such as age, gender, tumor stage, pathological grade, histological vein invasion, tumor size, tumor necrosis, Eastern Cooperative Oncology Group performance status (ECOG PS), symptoms (flank pain, flank mass, and hematuria), UCLA Integrated Staging System (UISS) \[[@B10]\] and biochemical parameters \[e.g., levels of hemoglobin (Hb), lactate dehydrogenase (LDH), calcium (Ca) and C-reactive protein (CRP)\] were collected. Tumor stage was determined on the basis of the 2009 TNM classification of the Union for International Cancer Control. Pathological grade was determined on the basis of the General Rules for Clinical and Pathological Studies on Renal Cell Carcinoma in Japan (pathological grade was classified as G1--G3). UISS incorporates the 1997 TNM classification, ECOG PS and pathological grade \[[@B10]\]. The cut-off level of LDH was determined to be 1.5 times the upper limit of normal (ULN). Corrected serum Ca was calculated as follows: total Ca + (4 − albumin). Tumor size, CRP and anemia were dichotomized as follows: tumor size, \<5 cm vs. ≥5 cm, CRP, ≤1.0 vs. \>1.0 mg/dL, and anemia, ≤13 vs. \>13 g/dL in males and ≤11.5 vs. \>11.5 g/dL in females \[[@B11],[@B12]\]. The Ethics Committee of the University of Kyorin approved this study. Informed consent was obtained from all patients.

Blood samples
-------------

Serum samples were obtained before nephrectomy from a peripheral vein. An 8.5 mL blood sample was taken and after clotting, the blood sample was centrifuged at 2000 rpm for 10 min. Serum was then stored at -80°C in 1 mL aliquots until analysis. A VEGF assay was performed using a commercial quantitative immunoassay kit for human VEGF165 (Quantikine, Human VEGF immunoassay, R&S Systems, Minneapolis, MN, USA). Serum samples (100 μL) were added to a 96-well microtiter plate coated with purified antihuman VEGF mouse IgG monoclonal antibodies and incubated at room temperature for 2 h. After washing, 200 μL of the secondary antibody solution, containing VEGF-specific polyclonal goat antibodies, was added and incubated for 2 h at room temperature. Substrate solution was added and the reaction continued for 25 min. Absorbance was measured at 450 nm using a microtiter plate reader (EMax, Molecular Devices, Sunnyvale, CA, USA). The sensitivity of the assay was 9 pg/ml, and coefficients of variance ranged from 4.5--6.7% and from 6.2--8.8% within and between assays, respectively.

Tissue samples
--------------

Paraffin block sections were available for all cases. Representative hematoxylin and eosin-stained specimens were reviewed to assess the histological type, histological vein invasion, tumor necrosis and pathological grade as well as to select sections for IHC. Cancer tissue samples for IHC analysis were selected from the site of highest pathological grade.

IHC
---

IHC was performed on 5 μm paraffin-embedded tissue sections placed on poly-[l]{.smallcaps}-lysine-coated glass slides. After heat drying, sections were deparaffinized in xylene and rehydrated in a series of graded ethanol solutions. Endogenous peroxidase was blocked with 0.3% hydrogen peroxide for 5 min at room temperature. For antigen retrieval, sections were immersed in a 0.01 mol/L sodium citrate buffer (pH 6.0), heated in a 600 W microwave for 4 min (twice) and allowed to cool for 30 min at room temperature. The slides were incubated at room temperature for 30 min with a polyclonal anti-VEGF antibody that detects the 189-, 165-, and 121-amino acid splice variants of human VEGF (sc-152; titer, 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA). A biotin-streptavidin detection system (Dako, Glostrup, Denmark) was subsequently applied using diaminobenzidine as the chromogen. As a negative control, phosphate-buffered saline or a normal rabbit immunoglobulin fraction diluted to the same protein concentration as the primary antibody was used. A pathologist independently evaluated the immunostaining. Staining was semiquantitatively assessed on the basis of a four-grade scale (0, absence of faint membrane staining in most tumor cells (\<20%); 1+, membrane staining of most tumor cells; 2+, diffuse membrane staining and cytoplasmic staining of groups of tumor cells (\<50%); and 3+, significant cytoplasmic staining in most cells). A score of 2+ or above was considered positive \[[@B7]\].

Statistics
----------

Variables were compared between the different groups using the Mann-Whitney *U* and Kruskal-Wallis tests. Independence of fitness of the categorical data was estimated using the χ^2^ test. Recurrence-free survival rates were calculated from the date of nephrectomy to the recognized date of recurrence. The recurrence-free survival rate was calculated using the Kaplan-Meier method, and the significance of comparisons between groups was measured using the log-rank test. A multivariate analysis was performed using a Cox proportional hazards regression model. The optimal serum VEGF value to discriminate recurrence, calculated using receiver operating characteristic (ROC) curve analysis. *P*-values of \<0.05 were considered statistically significant. All statistical analyses were performed using statistical software available commercially (SPSS v.18.0).

Results
=======

Patient characteristics are shown in Table [1](#T1){ref-type="table"}. Mean age of the patients was 65.0 ± 12.4 years. The mean follow-up duration was 52.6 ± 31.2 months (range, 3--139 months). Twelve patients (14.5%) had recurrence after surgery. The recurrence sites were as follows: lung (9 patients, 75%), bone (2 patients, 17%) and retroperitoneum (1 patient, 8%). In the recurrence group, four patients (33.3%) were treated with molecular-targeted therapy and two patients (16.7%) were treated with interferon therapy after recurrence. Two patients were performed prophylactic interferon therapy for one year, and they did not have recurrence. There was no significant association between prophylactic interferon therapy and recurrence (*P* = 0.556). Tumor stage, pathological grade, tumor necrosis, UISS, gender, hemoglobin, serum VEGF level and VEGF IHC-expression were significantly associated with recurrence (Table [1](#T1){ref-type="table"}).

###### 

Patient characteristics in relation to without and with recurrence CCRCC

  **Characteristic**               **Total**           **Without recurrence group**   **With recurrence group**   **P-value**
  -------------------------------- ------------------- ------------------------------ --------------------------- -------------
  Age (years)                                                                                                      
   Median \[range\]                67 \[23-83\]        67 \[23-83\]                   65 \[44-82\]                0.820
  Gender (%)                                                                                                       
   Male                            52 (63)             48 (68)                        4 (33)                       
   Female                          31 (37)             23 (32)                        8 (67)                      0.049
  ECOG PS (%)                                                                                                      
   0                               81 (98)             70 (99)                        11 (92)                      
   1                               1 (1)               1 (1)                          0 (0)                        
   2                               1 (1)               0 (0)                          1 (8)                       0.046
  T stage (%)                                                                                                      
   T1                              64 (77)             60 (85)                        4 (33)                       
   T2                              5 (6)               4 (5)                          1 (9)                        
   T3                              14 (17)             7 (10)                         7 (58)                       
   T4                              0 (0)               0 (0)                          0 (0)                       \<0.001
  Grade (%)                                                                                                        
   1                               7 (8)               5 (7)                          2 (17)                       
   2                               70 (84)             64 (90)                        6 (50)                       
   3                               6 (8)               2 (3)                          4 (33)                      \<0.001
  UISS risk classification (%)                                                                                     
   Low risk                        61 (73)             58 (82)                        3 (25)                       
   Intermediate risk               21 (25)             13 (18)                        8 (67)                       
   High risk                       1 (2)               0 (0)                          1 (8)                       \<0.001
  Histological vein invasion (%)                                                                                   
   No                              53 (64)             48 (68)                        5 (42)                       
   Yes                             30 (36)             23 (32)                        7 (58)                      0.083
  Tumor necrosis (%)                                                                                               
   No                              70 (84)             64 (90)                        6 (50)                       
   Yes                             13 (16)             7 (10)                         6 (50)                      \<0.001
  Symptoms (%)                                                                                                     
   No                              59 (71)             52 (73)                        7 (58)                       
   Yes                             24 (29)             19 (27)                        5 (42)                      0.292
  IHC staining (%)                                                                                                 
   Grade 0                         39 (47)             37 (52)                        2 (17)                       
   Grade 1+                        18 (22)             15 (21)                        3 (25)                       
   Grade 2+                        19 (23)             15 (21)                        4 (33)                       
   Grade 3+                        7 (8)               4 (6)                          3 (25)                      0.045
  Tumor size (mm)                                                                                                  
   Median \[range\]                40.0 \[12-120\]     40.0 \[12-90\]                 43.5 \[30-120\]             0.118
  Hemoglobin (g/dL )                                                                                               
   Median \[range\]                13.4 \[8.1-17.0\]   13.55 \[9.6-17.0\]             12.2 \[8.1-14.7\]           0.014
  Corrected Ca (mg/dL)                                                                                             
   Median \[range\]                9.30 \[8.5-11.2\]   9.25 \[8.5-10.8\]              9.35 \[8.6-11.2\]           0.606
  CRP (mg/dL)                                                                                                      
   Median \[range\]                0.20 \[0.0-12.4\]   0.20 \[0.0-12.4\]              0.35 \[0.0-6.2\]            0.335
  Serum VEGF (pg/mL)                                                                                               
   Median \[range\]                299 \[42-1460\]     290 \[42-1460\]                478 \[140-982\]             0.038

The median serum level of VEGF in 83 patients was 299 pg/mL (range, 42--1460 pg/mL). The serum VEGF level in patients with recurrence was significantly higher than in those without recurrence (*P* = 0.038). The serum VEGF level was significantly associated with pathological grade (*P* = 0.024), however, it was not significantly associated with tumor stage, histological vein invasion or UISS risk classification (*P* = 0.109, 0.193, and 0.282, respectively) (Table [2](#T2){ref-type="table"}). The cut-off value (416 pg/mL) of serum VEGF was determined using ROC analysis. Patients with a high serum VEGF level had significantly lower recurrence-free survival rates than those with a low serum VEGF level (*P* = 0.003; Figure [1](#F1){ref-type="fig"}).

###### 

Patient characteristics in relation to serum VEGF levels and IHC tissue staining of VEGF

  **Characteristic**           **VEGF levels**            **IHC tissue staining of VEGF**             
  ---------------------------- ------------------ ------- --------------------------------- --------- ---------
  Patient                                                 26                                57         
  Gender                                                                                               
   Male                        314\[42-1460\]             13 (50)                           39 (68)    
   Female                      290\[52-912\]      0.890   13 (50)                           18 (32)   0.107
  T stage                                                                                              
   T1                          313\[42-1330\]             16 (65)                           48 (84)    
   T2                          140\[50-353\]              4 (15)                            1 (2)      
   T3                          294\[79-1460\]             6 (23)                            8 (14)     
   T4                          \-                 0.109   0 (0)                             0 (0)     0.023
  Grade                                                                                                
   1                           519\[290-912\]             1 (4)                             6 (11)     
   2                           283\[42-1460\]             19 (73)                           51 (89)    
   3                           385\[225-982\]     0.024   6 (23)                            0 (0)     \<0.001
  UISS risk classification                                                                             
   Low risk                    313\[42-1330\]             14 (57)                           47 (82)    
   Intermediate risk           282\[50-1460\]             11 (42)                           10 (18)    
   High risk                   982                0.282   1 (4)                             0 (0)     0.014
  Histological vein invasion                                                                           
   No                          325\[42-1460\]             15 (58)                           38 (67)    
   Yes                         279\[79-1330\]     0.198   11 (42)                           19 (33)   0.430
  Tumor necrosis                                                                                       
   No                          288\[42-1460\]             22 (85)                           48 (84)    
   Yes                         405\[93-982\]      0.153   4 (15)                            9 (16)    0.962
  IHC staining                                                                                         
   Grade 0                     313 \[42-968\]             \-                                \-         
   Grade 1+                    325 \[91-511\]             \-                                \-         
   Grade 2+                    248 \[50-1460\]            \-                                \-         
   Grade 3+                    507 \[140-1330\]   0.378   \-                                \-         
  Recurrence                                                                                           
   No                          290\[42-1460\]             19 (73)                           52 (91)    
   Yes                         478\[140-982\]     0.038   7 (27)                            5 (9)     0.043

![**Kaplan-Meier analysis of recurrence-free survival rates: comparison between patients with high and low serum VEGF levels.** VEGF concentrations were determined before surgery. The solid line represents serum VEGF \>416 pg/mL (n = 22) and the dotted line represents serum VEGF ≤416 pg/mL (n = 61). Patients with VEGF \>416 pg/mL had a significantly increased risk of recurrence compared with those with VEGF ≤416 pg/mL (*P* = 0.003).](1756-0500-7-369-1){#F1}

Expression of VEGF using IHC is shown in Figure [2](#F2){ref-type="fig"}. Twenty-six patients (31.3%) were positive for VEGF expression. There was no significant association between serum levels and IHC-expression of VEGF (IHC expression Grade 0: 313 pg/mL, Grade 1+: 325 pg/mL, Grade 2+: 248 pg/mL, Grade 3+: 507 pg/mL; *P* = 0.378). VEGF IHC-expression was significantly associated with tumor stage, tumor grade, UISS risk classification and recurrence (Table [2](#T2){ref-type="table"}). Patients positive for VEGF had significantly lower recurrence-free survival rates than those negative for VEGF IHC-expression (*P* = 0.044; Figure [3](#F3){ref-type="fig"}).

![**IHC staining of VEGF in CCRCC. (A)** No staining or membrane staining was observed in \<20% of the tumor cells (grade 0); **(B)** Membrane without cytoplasmic immunostaining of tumor cells (grade 1+); **(C)** Diffuse membrane and cytoplasmic staining in \<50% of tumor cells (grade 2+); and **(D)** Significant cytoplasmic staining in most tumor cells (grade 3+). Magnification was 400 × .](1756-0500-7-369-2){#F2}

![**Kaplan-Meier analysis of recurrence-free survival rates: comparison between patients positive and negative for VEGF expression using IHC.** The solid line represents the IHC-positive group (n = 26), and the dotted line represents the IHC-negative group (n = 57). The IHC-positive group had a significantly increased risk of recurrence compared with the IHC-negative group (*P* = 0.044)](1756-0500-7-369-3){#F3}

Tumor stage, pathological grade, histological vein invasion, tumor necrosis, UISS, female gender, anemia, CRP, serum VEGF level and VEGF IHC-expression were significant univariate factors in predicting postoperative recurrence. A multivariate Cox logistic regression analysis showed that the preoperative serum level of VEGF and female gender were the only independent predictors of recurrence after radical nephrectomy (Table [3](#T3){ref-type="table"}).

###### 

Univariate and multivariate analyses to predict postoperative recurrence

  **Variable**          **Univariate**   **Multivariate**                                                                
  --------------------- ---------------- ------------------ --------- ------------------------ ------------------------- -------
  T stage               1 + 2            69                 5 (7)                              1.0 (ref)                  
  3 + 4                 14               7 (50)             \<0.001   4.376 (0.186--103.189)   0.360                     
  Grade                 1 + 2            77                 8 (10)                             1.0 (ref)                  
  3                     6                4 (67)             \<0.001   2.224 (0.091--54.113)    0.624                     
  Histological          No               53                 5 (9)                              1.0 (ref)                  
   Vein invasion        Yes              30                 7 (23)    0.033                    1.585 (0.248--10.120)     0.626
  Tumor size            \<5 cm           54                 7 (13)                                                        
  ≥5 cm                 29               5 (17)             0.549                                                        
  Symptoms              No               59                 7 (12)                                                        
  Yes                   24               5 (21)             0.195                                                        
  Tumor necrosis        No               70                 6 (9)                              1.0 (ref)                  
  Yes                   13               6 (46)             \<0.001   4.023 (0.523--30.944)    0.181                     
  UISS                  Low              61                 3 (5)                              1.0 (ref)                  
  Intermediate + high   22               9 (41)             \<0.001   7.373 (0.434--125.320)   0.170                     
  Gender                Male             52                 4 (8)                              1.0 (ref)                  
  Female                31               8 (26)             0.017     13.869 (2.354--81.713)   0.004                     
  ECOG PS               0                81                 11 (14)                                                       
  ≥1                    2                1 (50)             0.146                                                        
  Age                   \<65             48                 6 (12)                                                        
   (years)              ≥65              35                 6 (17)    0.809                                               
  Anemia                No               60                 6 (10)                             1.0 (ref)                  
  Yes                   22               6 (27)             0.035     1.536 (0.197--11.972)    0.682                     
  Missing               1                                                                                                
  LDH                   ≤1.5 × ULN       71                 11 (15)                                                       
  \>1.5 × ULN           2                0 (0)              NA                                                           
  Missing               10                                                                                               
  Corrected Ca          ≤10              71                 10 (14)                                                       
   (mg/dL)              \>10             8                  1 (12)    0.781                                               
  Missing               4                                                                                                
  CRP                   ≤1.0             70                 8 (11)                             1.0 (ref)                  
   (mg/dL)              \>1.0            12                 4 (33)    0.015                    0.476 (0.032--7.168)      0.591
  Missing               1                                                                                                
  Serum VEGF            ≤416             61                 4 (7)                              1.0 (ref)                  
   (pg/mL)              \>416            22                 8 (36)    0.003                    18.059 (1.853--176.019)   0.013
  IHC staining          Negative         57                 5 (9)                              1.0 (ref)                  
  Positive              26               7 (27)             0.044     1.130 (0.160--7.967)     0.902                     

NA: not available, ref: reference.

Discussion
==========

Angiogenesis is essential for tumor development and metastasis. VEGF plays a major role in stimulating the formation of new blood vessels in several biological processes including tumor angiogenesis \[[@B13]\]. CCRCC is a highly angiogenic tumor that secretes VEGF \[[@B14]\]. The Kattan postoperative nomogram and UISS are widely used to predict tumor recurrence after treatment of RCC \[[@B10],[@B15]\]; however, improved methods of prediction are required, and attempts to find better prognostic criteria are ongoing. This study showed that preoperative serum levels of VEGF may be a useful predictor of postoperative recurrence in patients with nonmetastatic CCRCC.

Rioux-Leclercq *et al.* reported that the expression of VEGF, assessed using IHC, in CCRCC tumors from 50 patients with a median follow-up of 11 months, was significantly associated with plasma VEGF levels, measured using an enzyme-linked immunoassay. Both expression of VEGF, using IHC, and plasma VEGF levels were significantly correlated with Fuhrman grade and tumor stage. VEGF IHC-expression correlated significantly with progression (*P* \< 0.01); however, there was insignificant difference in plasma VEGF levels between patients with and without progression (*P* = 0.06) \[[@B16]\].

There are several possible explanations for the discrepancy between the study by Rioux-Leclercq *et al.* and our study. First, both the studies were evaluated using a small sample size and short follow-up period. Second, tumor size affects the amount of circulating tumor-derived VEGF \[[@B17]\]; therefore, serum levels of VEGF may be higher in patients with larger tumors even if tumor cells express a similar level of VEGF. Third, variability in VEGF isoforms may affect the correlation between serum VEGF levels and expression of VEGF using IHC. VEGF has five isoforms (VEGF206, 189, 165, 145 and 121). In the present study, only VEGF189, 165 and 121 were assessed using IHC because high expression of these forms has been reported in RCC \[[@B18]\]. VEGF165 was selected for serum determination because VEGF165 and VEGF121 are the predominant isoforms secreted by most tumors \[[@B19]\]. The relationship between the pattern of VEGF isoforms synthesized in tumors and their concentration in the circulation remains unclear and warrants further study. Fourthly, bias could exist in assessing VEGF levels in plasma or serum samples. Serum samples contain high levels of VEGF due to its release by activated platelets during clotting \[[@B20]\]. Several studies reported a correlation between platelet counts and serum VEGF, and higher serum VEGF levels per platelet in cancer patients \[[@B21],[@B22]\]. Niers *et al.* reported that elevated plasma VEGF levels in blood samples were highly dependent on the method of collection and platelet VEGF content. Therefore, for the purpose of avoiding platelet activation *ex vivo*, blood samples were collected drop by drop without using a tourniquet \[[@B23]\].

Studies have shown that elevated serum levels of VEGF are associated with disease prognosis \[[@B6],[@B24]\]. Previously, we reported that the pretreatment serum level of VEGF correlated with postoperative recurrence in patients with nonmetastatic CCRCC \[[@B9]\]. In this study, we extended the mean period of follow-up (33.9 ± 27.2 to 52.6 ± 31.2 months), and evaluated VEGF using both serum analysis and immunohistochemical assay. The number of patients with recurrence increased from 8 to 12, but the cut-off value using ROC analysis was the same. Jacobsen *et al.* reported that serum levels of VEGF, assessed using a cut-off value of 343.5 pg/mL, as determined using the median value measured in 164 patients with RCC including various histological subtypes, significantly correlated with tumor stage, pathological grade and prognosis \[[@B6]\]. On the other hand, Tanimoto *et al.* reported that serum VEGF levels measured using the same methodology as in the Jacobsen *et al.* study and assessed using a cut-off value (400 pg/mL), as determined using ROC analysis in 45 patients with CCRCC, were not significantly correlated with tumor stage, pathological grade, tumor size or prognosis \[[@B25]\]. With regard to the relationship between histological subtype and serum levels of VEGF, there was no significant difference in serum VEGF levels between papillary RCC and CCRCC. However, serum VEGF levels in chromophobe RCC were found to be significantly lower than those in CCRCC \[[@B6]\]. The discordant result may be attributed to differences in RCC histological subtypes in subjects and the method used to calculate the cut-off value.

Based on IHC data, several investigators have reported that VEGF overexpression in CCRCC was associated with tumor stage, pathological grade, histological vein invasion and prognosis \[[@B7],[@B8]\]. In contrast, Verheul *et al.* reported that VEGF expression using IHC in CCRCC was not significantly correlated with prognosis \[[@B26]\]. This discrepancy in IHC results could be due to several factors including differences in fixation, scoring and staining methods \[[@B7],[@B8],[@B26]\].

Predictive factors of recurrence after nephrectomy in patients with RCC include anatomical (TNM classification), histological (pathological grade, histological vein invasion and tumor necrosis), clinical (symptoms and performance status) and biochemical (level of CRP) features \[[@B10]-[@B12],[@B15],[@B27],[@B28]\]. A major prognostic model for localized RCC is the UISS that combines TNM stage, Fuhrman grade and ECOG PS \[[@B10]\]. In our study, symptoms, ECOG PS and tumor size were not significant predictive factors of postoperative recurrence in patients with nonmetastatic CCRCC. The present study showed that female patients had a significantly poorer recurrence-free survival rate than male patients. However, Leibovich *et al.* reported no significant relationship between gender and prognosis in 1671 patients with CCRCC \[[@B27]\]. The gender difference in postoperative recurrence in our study may be due to the small number of enrolled patients and the retrospective nature of our study.

In RCC, few studies have investigated VEGF as a predictor of postoperative recurrence. However, several studies in patients with esophageal, hepatocellular and colorectal carcinomas showed that elevation of serum VEGF levels might be a predictor for poor recurrence-free survival \[[@B29]-[@B31]\]. The present study had some limitations. First, the relatively small sample size may produce false-positive results, or over-estimate the magnitude of an association. Second, the short follow-up time may be insufficient to observe recurrence. Third, this was a retrospective study, which was susceptible to selection bias. A larger study and one with more balanced groups (i.e. patients with and without recurrence) will produce more precise estimates. Further large prospective studies are needed to confirm our results.

Conclusions
===========

Our study showed that measurement of preoperative VEGF serum levels in patients with nonmetastatic CCRCC may be more useful than using IHC to assess VEGF expression in tumor tissues for prediction of postoperative recurrence after nephrectomy.
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